Expression of transforming growth factors beta (1, 2, 3) and connective tissue growth factor in the peripheral lung from GOLD stage 1-2 COPD patients and smokers with normal lung function
G. Caramori, M. McLeish, A. Lewis, P. Monk, P. Casolari, K. Ito, K. F. Chung, I. M. Adcock, P. J. Barnes, A. Papi (Ferrara, Italy; Cambridge, London, United Kingdom)
Source: Annual Congress 2006 - Recent advances in the treatment of COPD and acute lung injury
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Caramori, M. McLeish, A. Lewis, P. Monk, P. Casolari, K. Ito, K. F. Chung, I. M. Adcock, P. J. Barnes, A. Papi (Ferrara, Italy; Cambridge, London, United Kingdom). Expression of transforming growth factors beta (1, 2, 3) and connective tissue growth factor in the peripheral lung from GOLD stage 1-2 COPD patients and smokers with normal lung function. Eur Respir J 2006; 28: Suppl. 50, 3848
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Expression of transforming growth factor β (TGFβ) receptor, CD105, is declined in Th1 interstitial lung diseases (ILDs) Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011
Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012
Down regulation of stromal cell-derived factor 1 (SDF-1/CXCL12) in lung tissue of patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007
Transforming growth factor beta 1 (TGF-ß1) level as a marker of COPD severity Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Overexpression of B cell activating factor (BAFF) in peripheral lung of COPD patients Source: Annual Congress 2009 - Pathology and immunology of COPD Year: 2009
Late-breaking abstract: Relationship of aquaporin 1, 3 and 5 expression in lung cancer cells to cellular differentiation, invasive growth and metastasis potential Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF) Source: Eur Respir J 2004; 24: Suppl. 48, 553s Year: 2004
Expression of epidermal growth factor receptor (EGFR) in the bronchial epithelium of patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011
Epidermal growth factor (EGF) and its receptors (ERBBs) in smokers with and without COPD: An index of epithelial repair imbalance? Source: Annual Congress 2012 - The smoking gun in COPD biology Year: 2012
Influence of tobacco-smoking on serum level of transforming growth factor (TGF) beta 1 in COPD patients Source: International Congress 2017 – COPD biomarkers Year: 2017
Haemophilus influenzae (NTHi) up-regulates acute inflammation in human lung tissue and causes downregulation of transforming growth factor-beta (TGF-beta) – A possible role of NTHi in remodeling processes in human lung tissueSource: Annual Congress 2010 - Novel cellular mechanisms in lung disease Year: 2010
Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF) Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009
Resistance of BAL immune cells to apoptosis in interstitial lung diseases (ILD) with high local tumor necrosis factor-α (TNFα) levels as a possible consequence of common TNF receptor type 2 expression Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008
Expression of transforming growth factor (TGF) in bronchial epithelium: association with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 92s Year: 2001
Relationship between level of transforming growth factor beta 1 (TGF beta 1) and serum amyloid A in COPD patients Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019
The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis. Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes Year: 2018
MUC5AC and MUC5B expression in central airways from non-smokers, smokers with normal lung function and GOLD stage 1 and 2 COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006
Placenta growth factor (PlGF) triggers small airway remodeling (SAR) in chronic obstructive pulmonary disease (COPD) Source: International Congress 2017 – Insight into the pathogenesis of emphysema and pneumonia Year: 2017